Sanaria's Malaria Vaccine Yields Unprecedented Protection in Phase 1 Clinical Trial
Aug 8 13
Results of a phase I clinical trial of the Sanaria(R) PfSPZ Vaccine to combat malaria, published in the online issue of Science magazine, show that the vaccine provided complete protection against malaria in subjects who were exposed to Plasmodium falciparum parasites. Plasmodium falciparum is the malaria parasite that causes more than 600,000 deaths annually. The current trial was primarily funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) with additional support from the Naval Medical Research Center and Sanaria. Sanaria has also received research support and funding from multiple other institutions in the United States, Europe, and Africa during the past decade and will continue its fund-raising efforts to expand its research and clinical programs. In the clinical trial reported in Science, volunteers received intravenous injections of Sanaria(R) PfSPZ Vaccine, which consists of live, weakened, purified malaria parasites that do not cause illness. None of the six volunteers who received the higher dosage developed malaria after being bitten by malaria parasite-infected (disease transmitting) mosquitoes. The trial included 40 adult volunteers, ages 20-44, enrolled, vaccinated and assessed under the direction of the principal investigator, Robert Seder, M.D., and clinical team at the Vaccine Research Center, NIAID, NIH, Bethesda, MD.
Sanaria, Inc. Presents at World Vaccine Congress Washington 2013, Apr-16-2013 06:20 PM
Mar 26 13
Sanaria, Inc. Presents at World Vaccine Congress Washington 2013, Apr-16-2013 06:20 PM. Venue: Gaylord National Hotel and Convention Center, Washington, District Of Columbia, United States. Speakers: Stephen Hoffman, Chief Executive Officer.